Clinical trials: Phobia
Social Phobia
A Study To Evaluate The Effect Of GW876008 On The Pharmacokinetics Of Oral Contraceptive Pills
This study will be conducted in healthy female volunteers to investigate the effect of GW876008 on the pharmacokinetics of oral contraceptive pills.
- Trial name
- NCT00508911
- Testing
- GW876008, COC
- Where
- United Kingdom
- Volunteers
- 4 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Social Anxiety Disorder
Escitalopram in Patients With Social Anxiety Disorder
The purpose of this study is to evaluate the effect of escitalopram after 12 weeks of treatment in patients with Social Anxiety Disorder (SAD), to evaluate proportion of patients who respond to escitalopram during the treatment…
- Trial name
- NCT00902226
- Testing
- Escitalopram
- Where
- Russia
- Volunteers
- 30 people
- Sponsor
- H. Lundbeck A/S
Social Phobia
Long-term Study Of Paroxetine in Women and Men
This study is designed to evaluate the efficacy and safety in Social Anxiety Disorder (SAD)
- Trial name
- SAD (NCT00264654)
- Testing
- BRL29060A, paroxetine hydrochloride hydrate
- Where
- 3 sites in Japan
- Volunteers
- 50 people
- Sponsor
- GlaxoSmithKline
Social Anxiety Disorder
A Phase 2 Study of BNC210 for the Acute Treatment of Social Anxiety Disorder
The purpose of this study is to assess the effects of an acute dose of BNC210 compared to placebo on reducing anxiety provoked by a speaking challenge and measured using the Subjective Units of Distress Scale (SUDS) in patients…
- Trial name
- PREVAIL (NCT05193409)
- Testing
- 225 mg BNC210, 675 mg BNC210
- Where
- 15 sites in United States
- Volunteers
- 151 people
- Sponsor
- Bionomics Limited
Social Phobia
A Combination Therapy In Patients With Social Anxiety Disorder
The purpose of this study is to assess the efficacy, safety and tolerability of a combination of Vestipitant and Paroxetine in patients with Social Anxiety Disorder (SAD)
- Trial name
- NCT00403962
- Testing
- vestipitant/paroxetine
- Where
- 17 sites in Denmark, Germany and 2 more
- Volunteers
- 204 people
- Sponsor
- GlaxoSmithKline
Needle Phobia, Phobic Disorders
Effect of Including Synera® in Discussions on Dialysis Access Conversion in Patients With Needle Phobias
An arteriovenous fistula or graft access (AVF/AVG) for dialysis is often considered a superior option for delivery of dialysis, but requires needles to be inserted.
- Trial name
- NCT01623583
- Testing
- Enhanced Needle Phobia Intervention, Standard Needle Phobia Intervention
- Where
- 3 sites in United States
- Volunteers
- 10 people
- Sponsor
- Davita Clinical Research
Social Anxiety Disorder
PH94B Nasal Spray for Anxiety Induced by a Public Speaking Challenge - 2
This Phase 3 clinical trial is designed to evaluate the efficacy, safety, and tolerability of the acute administration of 3.2 µg of PH94B to relieve symptoms of anxiety in adult subjects with social anxiety disorder (SAD) during…
- Trial name
- Palisade-2 (NCT05011396)
- Testing
- PH94B Nasal Spray
- Where
- 15 sites in United States
- Volunteers
- 228 people
- Sponsor
- VistaGen Therapeutics, Inc.
Generalized Anxiety Disorder (GAD), Anxiety, Separation
SPD503 in Subjects Aged 6-17 Years With Generalized Anxiety Disorder (GAD), Separation Anxiety Disorder (SAD), or Social Phobia (SoP)
This study will evaluate the safety and tolerability of SPD503 in subjects aged 6-17 years with GAD, SAD, or SoP based on treatment emergent adverse events (TEAEs), vital signs and ECGs.
- Conditions
- Generalized Anxiety Disorder (GAD), Anxiety, Separation, Phobia, Social
- Trial name
- NCT01470469
- Testing
- SPD503 (extended-release Guanfacine hydrochloride)
- Where
- 33 sites in United States
- Volunteers
- 83 people
- Sponsor
- Shire
Social Anxiety, Social Anxiety Disorder
The Safety, Acceptability and Efficacy of Alena
The present study is a randomised controlled trial that seeks to investigate the safety, acceptability and efficacy and safety of the Alena CBT programme as a treatment for social anxiety disorder.
- Conditions
- Social Anxiety, Social Anxiety Disorder, Social Anxiety Disorder (Social Phobia)
- Trial name
- NCT05858294
- Testing
- Cognitive Behavioral Therapy programme
- Where
- United Kingdom
- Volunteers
- 102 people, healthy volunteers welcome
- Sponsor
- Aya Technologies Limited
Social Anxiety Disorder (SAD)
A Study to Evaluate the Efficacy and Safety of ENX-102 in Participants With Social Anxiety Disorder
This is a double-blind study to evaluate the efficacy and safety of ENX-102 in participants with social anxiety disorder (SAD).
- Trial name
- NCT07193563
- Testing
- ENX-102
- Where
- 20 sites in United States
- Volunteers
- 47 people
- Sponsor
- Engrail Therapeutics INC
Vitiligo, Depressive Episode
Mental Health Associations With Vitiligo
This cohort study is a large population-based study in the UK to determine the risks of comorbid mental health conditions (including depression, anxiety and other potential psychological complications of vitiligo) in adults with…
- Conditions
- Vitiligo, Depressive Episode, Recurrent Depressive Disorder, Anxiety Disorders
- Trial name
- NCT04953338
- Testing
- Exposure of mental health condtion of interest
- Where
- United Kingdom
- Volunteers
- 36,104 people, healthy volunteers welcome
- Sponsor
- Momentum Data
Social Anxiety Disorder
Efficacy of BNC210 in Acute, As-needed Treatment of Anxiety in Social Anxiety Disorder - 1
The purpose of the study is to evaluate the effect of a single, acute dose of BNC210 compared to placebo on reducing the severity of anxiety provoked by a behavioral assessment task and measured using the Subjective Units of…
- Trial name
- AFFIRM-1 (NCT06510504)
- Testing
- 225 mg BNC210
- Where
- 21 sites in United States
- Volunteers
- 370 people
- Sponsor
- Bionomics Limited
Depressive Disorder and Anxiety Disorders
PET (Positron Emission Tomography)/Public Speaking Study With A Combination Of 2 Medications In Social Anxiety Patients
This six-arm study is being conducted to measure the effect of a combination of paroxetine and vestipitant on the arousal induced by public speaking in Seasonal Effective Disorder (SAD) patients, using functional brain imaging…
- Trial name
- NCT00343707
- Testing
- vestipitant, paroxetine
- Where
- Sweden
- Volunteers
- 72 people
- Sponsor
- GlaxoSmithKline
Social Anxiety Disorder (SAD)
A Study of NTX-1472 in Social Anxiety Disorder
The primary goal of this Phase 2 clinical trial is to determine the effects of a novel V1a receptor antagonist (NTX-1472) in adults with Social Anxiety Disorder (SAD).
- Trial name
- SOAR (NCT07323784)
- Testing
- NTX-1472
- Where
- 11 sites in United States
- Volunteers
- 100 people
- Sponsor
- Newleos Therapeutics, Inc.
Social Phobia
A Study To Compare The Putative Anxiolytic Effect Of 2 New Drugs In Subjects With Social Anxiety Disorder
To compare by neuroimaging techniques and public speaking, the way social anxiety patients respond after the administration of GW876008, GSK561679, alprazolam and placebo
- Trial name
- NCT00555139
- Testing
- GSK561679 tablet, GW876008 tablet, alprazolam
- Where
- 8 sites in Spain
- Volunteers
- 35 people
- Sponsor
- GlaxoSmithKline
Claustrophobia, Complication of Diagnostic Procedure
Comfort Talk and Economic Outcomes in MRI
Annually, an estimated 700,000 patients do not complete their scheduled MRI scans because of claustrophobia or inability to hold still.
- Trial name
- ComfortTalk® (NCT02427737)
- Testing
- Comfort Talk® Training
- Where
- 3 sites in United States
- Volunteers
- 12 people
- Sponsor
- Hypnalgesics, LLC
Social Phobia
Treatment Of Patients With Social Anxiety Disorder
GW876008 is a drug which may change mans reaction to stress, by decreasing the fear, physical and behavior symptoms that people with SocAD experience in social situations.
- Trial name
- NCT00397722
- Testing
- GW876008, paroxetine
- Where
- 33 sites in United States, Canada and 5 more
- Volunteers
- 299 people
- Sponsor
- GlaxoSmithKline
Social Anxiety Disorder
A Clinical Trial to Assess the Efficacy, Safety, and Tolerability of a Repeat Dose of Fasedienol Nasal Spray for the Acute Treatment of Anxiety in Adults With Social Anxiety Disorder
This U.S. multicenter, double-blind, placebo-controlled Phase 2 clinical trial is designed to evaluate the efficacy, safety, and tolerability of a repeat intranasal (i.n.) dose of Fasedienol Nasal Spray (fasedienol) (3.2 µg) to…
- Trial name
- NCT06809179
- Testing
- Fasedienol Nasal Spray - Fasedienol Nasal Spray
- Where
- 9 sites in United States
- Volunteers
- 60 people
- Sponsor
- VistaGen Therapeutics, Inc.
Social Anxiety Disorder
Cannabidiol (CBD) for the Treatment of Social Anxiety Disorder
A phase 2, multicenter, double-blind, parallel group, placebo-controlled, randomized clinical study, designed to compare the efficacy, safety, and tolerability of 2 dose levels of CBD and a matching placebo for the treatment of…
- Trial name
- NCT05600114
- Testing
- Cannabidiol oral solution
- Where
- 17 sites in United States
- Volunteers
- 239 people
- Sponsor
- EmpowerPharm Inc.
Social Anxiety Disorder
CHI-902 for Treatment of Social Anxiety Disorder
No substantial clinical trials of Cannabidiol (CBD) in Social Anxiety Disorder (SAD) have yet been conducted. This randomized doubleblind, placebo-controlled trial of CBD in adults with SAD will evaluate the efficacy…
- Trial name
- NCT04086342
- Testing
- CHI-902
- Where
- 2 sites in Canada
- Volunteers
- healthy volunteers welcome
- Sponsor
- Canopy Growth Corporation